AIM ImmunoTech
Tracked across 3 events · 22 articles · First seen Feb 11, 2026 · Last active Jun 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: AIM ImmunoTech conducted a rights offering to raise capital, which resulted in approximately $1.8 million in subscriptions, significantly less than the initially expected $12 million, indicating a shortfall in fundraising.
Feb 11, 2026 · 6 articles
Tech
Impact: AIM ImmunoTech Inc. is the developer of Ampligen and is reporting positive interim results from its Phase 2 DURIPANC study, which could lead to significant value inflection for the company.
Jun 01, 2026 · 10 articles
Regulatory
Impact: AIM ImmunoTech Inc. regained compliance with NYSE American's listing standards, resolving its stockholders' equity deficiency through several financing transactions. This positive development removes the 'below compliance' indicator from its trading symbol and improves its market standing.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track AIM ImmunoTech live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard